These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31482070)

  • 1. Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma.
    Michel M; Hollenbach M; Pohl S; Ripoll C; Zipprich A
    Front Oncol; 2019; 9():785. PubMed ID: 31482070
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of glyoxalase-I is reduced in cirrhotic livers: A possible mechanism in the development of cirrhosis.
    Hollenbach M; Thonig A; Pohl S; Ripoll C; Michel M; Zipprich A
    PLoS One; 2017; 12(2):e0171260. PubMed ID: 28231326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glyoxalase-I Is Upregulated in Acute Cerulein-Induced Pancreatitis: A New Mechanism in Pancreatic Inflammation?
    Hollenbach M; Sonnenberg S; Sommerer I; Lorenz J; Hoffmeister A
    Antioxidants (Basel); 2021 Oct; 10(10):. PubMed ID: 34679710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC).
    Hollenbach M
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.
    Li A; Zhang R; Zhang Y; Liu X; Wang R; Liu J; Liu X; Xie Y; Cao W; Xu R; Ma Y; Cai W; Wu B; Cai S; Tang X
    Am J Transl Res; 2019; 11(9):5573-5585. PubMed ID: 31632530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy.
    Kong J; Yao C; Ding X; Dong S; Wu S; Sun W; Zheng L
    Front Oncol; 2020; 10():1080. PubMed ID: 32670888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced cytotoxicity of human hepatocellular carcinoma cells following pretreatment with sorafenib combined with trichostatin A.
    Chen JC; Chuang HY; Liao YJ; Hsu FT; Chen YC; Wang WH; Hwang JJ
    Oncol Lett; 2019 Jan; 17(1):638-645. PubMed ID: 30655811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.
    Wu FQ; Fang T; Yu LX; Lv GS; Lv HW; Liang D; Li T; Wang CZ; Tan YX; Ding J; Chen Y; Tang L; Guo LN; Tang SH; Yang W; Wang HY
    J Hepatol; 2016 Aug; 65(2):314-24. PubMed ID: 27154061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
    Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
    Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
    Zhang SS; Ni YH; Zhao CR; Qiao Z; Yu HX; Wang LY; Sun JY; Du C; Zhang JH; Dong LY; Wang K; Gao JJ
    Acta Pharmacol Sin; 2018 Mar; 39(3):438-448. PubMed ID: 29188798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Morisaki T; Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M
    Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Eltrombopag antitumor effect on hepatocellular carcinoma.
    Kurokawa T; Murata S; Zheng YW; Iwasaki K; Kohno K; Fukunaga K; Ohkohchi N
    Int J Oncol; 2015 Nov; 47(5):1696-702. PubMed ID: 26397763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
    Turcios L; Vilchez V; Acosta LF; Poyil P; Butterfield DA; Mitov M; Marti F; Gedaly R
    Dig Liver Dis; 2017 Jun; 49(6):697-704. PubMed ID: 28179093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.